Investor Presentaiton

Safeguard Scientifics, Inc. Overview Safeguard has an attractive venture portfolio of late-stage tech-enabled healthcare, digital media and other companies • Major sectors of exposure - ad tech and tech-enabled healthcare - are experiencing positive secular trends Portfolio has limited follow-on capital needs: $5-7mm guidance for 2021 - down from $9.2mm in 2020 Safeguard is pursuing a focused strategy to value-maximize and monetize its ownership interests over a multi-year time frame to drive shareholder value • Strict portfolio management and capital allocation approach to follow-on deployments and exits decisions • Year-to-date asset sale proceeds of $58 million, inclusive of the cash proceeds from the recently announced Flashtalking sale • • June IPO of Bright Health Group resulted in the conversion of Safeguard's preferred shares into 1.3 million shares of common stock, subject to lock up through end of December Since adoption of current strategy in January 2018, realized approximately $252 million in cash proceeds Progress towards returning capital to shareholders • • During Q2 2021, Safeguard repurchased 229,000 shares of common stock at an average cost of $6.93 per share (totaling $1.6 million) as part of $6 million share repurchase program initiated in May 2021 Targeted liquidity threshold (above which to consider returning capital) reduced in Q1 from $20 million to $18 million On Sept 2nd, Safeguard launched a self-tender offer to purchase up to $35mm of its common stock in a modified Dutch auction at prices between (and including) $7.90 to $9.00 per share Safeguard continues to reduce its corporate costs and increase its operating flexibility Committed to exploring all actions to maximize shareholder value Management and Board compensation aligned with shareholders' interests www.safeguard.com SFE © 2021 Safeguard Scientifics, Inc. All rights reserved. LISTED 3 NYSE

View entire presentation